New publication highlights safety and potential benefits of redosing Diamyd® precision medicine for Type 1 Diabetes

Diamyd Medical announces the publication of the article titled "Redosing with Intralymphatic GAD-Alum in the Treatment of Type 1 Diabetes: The DIAGNODE-B Pilot Trial" in the peer-reviewed journal International Journal of Molecular Sciences. The article describes the investigator-initiated clinical trial DIAGNODE-B, conducted in Linköping by Prof. Johnny Ludvigsson, which demonstrates the safety and potential efficacy of redosing Diamyd[®] (GAD-Alum), an antigen-specific immunotherapy aimed at preserving beta-cell function in Type 1 Diabetes. The trial included six participants carrying